查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836814

儿科疫苗市场（按疫苗类型、疾病、技术、最终用户和年龄划分）—2025-2032 年全球预测

Pediatric Vaccines Market by Vaccine Type, Disease, Technology, End User, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，儿科疫苗市场将成长 523 亿美元，复合年增长率为 11.90%。

主要市场统计数据
基准年2024年 212.6亿美元
预计2025年 238.3亿美元
预测年份：2032年 523亿美元
复合年增长率（%） 11.90%

重点介绍创新、政策、供应弹性和相关人员期望的交叉力量，这些力量决定了当代儿科疫苗策略

儿童疫苗接种仍然是我们这个时代最重要的公共卫生干预措施之一，其基础是临床科学、公共、采购架构和生产能力的复杂相互作用。过去十年，抗原设计、偶联技术和製剂组合方面的进步扩展了婴儿、儿童和青少年的预防套件包，使人们能够以更少的注射次数和更便捷的接种时间获得更广泛的保护。同时，流行病学的演变、家长期望的提高以及支付方优先事项的变化，迫使疫苗相关人员重新评估供应弹性和价值提案。

因此，製造、分销和公共卫生组织的领导者必须协调快速的技术进步与持续的营运现实。低温运输的完整性、跨辖区监管的一致性以及组合药物的经济性都会影响专案实施的可行性。因此，对这一领域的实际介绍必须突出技术创新如何转化为可部署的解决方案，同时认识到影响采用和获取的系统性限制因素。本摘要为深入探讨变革性转变、细分市场细微差别、区域差异以及建议的行动奠定了基础，旨在为近期的决策者指南。

影响儿科疫苗开发、生产和引进动态的主要技术、监管和供应模式转移的分析概述

儿科疫苗领域正在经历一场变革性转变，这得益于技术突破、政策重点转变以及新的给药模式，这些模式正在重新定义疫苗的设计、生产和给药方式。重组和结合技术的进步使得疫苗的抗原覆盖范围更广，免疫抗原性，而联合疫苗则减少了就诊次数，并简化了免疫接种程序。同时，製造商正在采用模组化和灵活的生产方式，以快速响应需求波动并支援本地化的供应链。

在政策方面，各方明显推动监管协调和加速核准框架，以缩短针对高负担儿童疾病的疫苗上市时间。筹资策略也不断发展，采购方强调整体拥有成本、供应保证条款以及培训和低温运输援助等生命週期服务。数位化健康和免疫登记系统开始支援更有针对性的推广和覆盖率监测，从而提高了衡量实际影响和根据持续存在的差异量身定制宣传活动的能力。公众信任和传播策略仍然至关重要，卫生当局和製造商应投资于透明的安全沟通和社区参与，以在不同人群中保持较高的疫苗接种率。

清楚评估近期关税措施如何影响供应链决策、筹资策略和儿科疫苗生产地理

2025年宣布的贸易政策变化，包括影响药品和生技药品投入的新关税措施，正在对儿科疫苗价值链产生累积影响，加剧成本压力，鼓励供应商多元化，并加速近岸外包谈判。特种佐剂、无菌灌装耗材和一次性生物反应器零件等原料已成为采购团队探索替代筹资策略以减轻关税影响的重点。因此，製造商和采购负责人重新审视了合约条款和库存策略，以确保免疫接种项目能够持续进行。

为应对这项挑战，一些製造商正在将投资转移到区域製造地，以降低跨境关税风险并缩短前置作业时间。由于建立能够生产生技药品的设施需要熟练的人员并遵守严格的品质框架，此类策略性迁移会影响东道国的监管趋同和劳动力发展。对采购者而言，关税环境凸显了透明的土地成本分析以及与供应商合作共担风险安排的重要性。最终，这些影响促使采购团队和政策制定者需要进行基于情境的规划，评估贸易政策的突发事件以及公共卫生优先事项，以维持弱势儿科族群的免疫接种机会。

全面的细分洞察，将产品类型、疾病目标、技术、最终用户管道和人口统计数据与策略临床和商业性影响联繫起来

細項分析揭示了产品、疾病、技术、最终用户和年龄组等类别如何推动儿科免疫计划的差异化开发和交付考虑。依疫苗类型，市场分为四类：六价、单价、五价和四价。六价製剂等联合疫苗强调程序上的便利性和时间压缩，而单价製剂在疫情应对和加强策略方面仍具有战略意义。依疾病，研究涵盖 DTP、B型肝炎、Hib、麻疹、肺炎链球菌、脊髓灰质炎和轮状病毒。对于 DTP，进一步的分析涵盖白喉、百日咳和破伤风。疾病特异性动态，例如肺炎链球菌感染的血清型多样性和轮状病毒的基因型多样性，影响抗原选择和监测重点。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大mRNA技术在儿科疫苗研发的应用，对抗新兴病原体
  • 增加联合疫苗的使用，以减轻儿童的注射负担
  • 传播数位追踪工具，提高儿童疫苗接种依从性和覆盖率
  • 更重视疫苗公平倡议，以扩大服务不足的儿科族群的疫苗接种机会
  • 开发无针给药方法以提高婴幼儿疫苗接种率

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 儿科疫苗市场（依疫苗类型）

  • 六价
  • 单身的
  • 五价
  • 四价

9. 儿科疫苗市场（依疾病）

  • DTP
    • 白喉
    • 百日咳
    • 破伤风
  • B型肝炎
  • 乙型流感嗜血桿菌
  • 麻疹
  • 肺炎球菌
  • 脊髓灰质炎
  • 轮状病毒

10.儿科疫苗市场（依技术）

  • 复杂类型
    • 多醣复合物
    • 蛋白质复合物
  • 惰性
    • 类毒素
    • 病毒性的
  • 减毒变态
    • 细菌
    • 病毒性的
  • 重组
    • 哺乳动物细胞培养
    • 酵母基
  • 次单元
    • 胜肽次单元
    • 蛋白质次单元

第 11 章儿科疫苗市场（依最终用户）

  • 诊所
    • 综合诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院
  • 疫苗接种中心
  • 药局
    • 医院药房
    • 零售药局

12. 儿童疫苗市场（依年龄层）

  • 青年
  • 孩子
  • 婴儿
  • 新生
  • 婴儿

13. 儿科疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章儿科疫苗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国儿科疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Sanofi SA
    • Serum Institute of India Private Limited
    • Bharat Biotech International Limited
    • PT Bio Farma（Persero）
    • Sinovac Biotech Ltd.
    • CSL Seqirus Pty Ltd.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-030EE4851566

The Pediatric Vaccines Market is projected to grow by USD 52.30 billion at a CAGR of 11.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.26 billion
Estimated Year [2025] USD 23.83 billion
Forecast Year [2032] USD 52.30 billion
CAGR (%) 11.90%

A focused introduction outlining the intersecting forces of innovation, policy, supply resilience, and stakeholder expectations that define modern pediatric vaccine strategies

Pediatric vaccination remains one of the most consequential public health interventions of the modern era, underpinned by complex interactions among clinical science, public policy, procurement architecture, and manufacturing capability. Over the past decade, advances in antigen design, conjugation techniques, and combination formulations have expanded the preventive toolkit for infants, toddlers, children, and adolescents, raising expectations for broader protection with fewer injections and simpler schedules. At the same time, evolving epidemiology, heightened parental expectations, and shifting payer priorities have pushed vaccine stakeholders to re-evaluate supply resilience and value propositions.

Consequently, leaders across manufacturing, distribution, and public health institutions must reconcile rapid technological progress with persistent operational realities. Cold chain integrity, regulatory alignment across jurisdictions, and the economics of combination products all influence the feasibility of programmatic uptake. Therefore, a pragmatic introduction to this landscape needs to foreground how innovation translates into deployable solutions, while acknowledging the systemic constraints that shape adoption and access. This summary sets the stage for a deeper examination of the transformative shifts, segmentation nuances, regional differentials, and recommended actions that will guide decision-makers in the near term.

An analytical overview of the major technological, regulatory, and delivery paradigm shifts reshaping pediatric vaccine development manufacturing and uptake dynamics

The pediatric vaccine landscape is experiencing transformative shifts driven by technological breakthroughs, altered policy priorities, and new delivery paradigms that collectively redefine how protection is designed, produced, and delivered. Advances in recombinant and conjugate technologies have enabled broader antigen coverage and improved immunogenicity, allowing combination vaccines to reduce clinic visits and streamline immunization schedules. Concurrently, manufacturers are adopting modular and flexible production approaches to respond faster to demand fluctuations and to support regionally localized supply chains.

On the policy side, there is a visible push toward harmonized regulatory pathways and accelerated approval frameworks to shorten time-to-market for vaccines that address high-burden pediatric diseases. Procurement strategies are also evolving; purchasers are increasingly weighing total cost of ownership, supply assurance clauses, and lifecycle services such as training and cold chain support. Digital health and immunization registries are beginning to underpin more targeted outreach and coverage monitoring, enhancing the ability to measure real-world impact and to tailor campaigns to persistent gaps. Public trust and communication strategies remain critical, with health authorities and manufacturers investing in transparent safety communication and community engagement to maintain high uptake across diverse populations.

A clear-eyed assessment of how recent tariff measures have influenced supply chain decisions procurement strategies and the geographic distribution of pediatric vaccine production

Trade policy changes announced in 2025, including new tariff measures affecting pharmaceuticals and biologics inputs, have had a cumulative impact on pediatric vaccine value chains by amplifying cost pressures, encouraging supplier diversification, and accelerating nearshoring conversations. Raw materials such as specialized adjuvants, consumables for aseptic filling, and single-use bioreactor components became focal points for procurement teams seeking alternative sourcing strategies to mitigate tariff exposure. As a result, manufacturers and procurers have re-examined contractual terms and inventory strategies to sustain uninterrupted immunization programs.

In response, some producers have shifted investments toward regional manufacturing hubs to reduce cross-border tariff risk and to shorten lead times. This strategic relocation has implications for regulatory convergence and workforce development in host regions, because establishing biologics-capable facilities demands skilled personnel and compliance with stringent quality frameworks. For purchasers, the tariff environment has heightened the importance of transparent landed cost analyses and collaborative risk-sharing arrangements with suppliers. Ultimately, these effects have reinforced the need for scenario-based planning, where procurement teams and policy-makers evaluate trade policy contingencies alongside public health priorities to preserve immunization access for vulnerable pediatric populations.

Comprehensive segmentation insights connecting product types disease targets technologies end-user channels and age cohorts to strategic clinical and commercial implications

Segmentation analysis reveals how distinct product, disease, technology, end-user, and age-group categories drive differentiated development and delivery considerations across pediatric immunization programs. Based on Vaccine Type, market is studied across Hexavalent, Monovalent, Pentavalent, and Quadrivalent; combination vaccines such as hexavalent formulations emphasize programmatic convenience and schedule compression, while monovalent products retain strategic relevance for targeted outbreak responses and booster strategies. Based on Disease, market is studied across DTP, Hepatitis B, Hib, Measles, Pneumococcal, Polio, and Rotavirus. The DTP is further studied across Diphtheria, Pertussis, and Tetanus; disease-specific dynamics-such as serotype diversity in pneumococcal disease or genotypic variation in rotavirus-inform antigen selection and surveillance priorities.

Based on Technology, market is studied across Conjugate, Inactivated, Live Attenuated, Recombinant, and Subunit. The Conjugate is further studied across Polysaccharide Conjugate and Protein Conjugate. The Inactivated is further studied across Toxoid and Viral. The Live Attenuated is further studied across Bacterial and Viral. The Recombinant is further studied across Mammalian Cell Culture and Yeast Based. The Subunit is further studied across Peptide Subunit and Protein Subunit; these technological distinctions have direct implications for manufacturing complexity, cold chain requirements, and immunogenicity profiles, shaping both R&D prioritization and capital expenditure decisions. Based on End User, market is studied across Clinics, Hospitals, Immunization Centers, and Pharmacies. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies; distribution and training investments need to align with the dominant end-user channels in a given geography to ensure timely availability and correct administration practices. Based on Age Group, market is studied across Adolescents, Children, Infants, Neonates, and Toddlers, and tailoring formulation, dosing regimen, and delivery mechanisms to the physiological and programmatic needs of each age cohort remains a core determinant of clinical adoption and program success.

Interacting across these segmentation axes, certain patterns emerge: combination vaccines and conjugate technologies trend toward integrated programmatic value, whereas recombinant and subunit platforms offer flexible upgrade pathways for antigenic modification. End-user distribution preferences condition packaging and presentation choices, and age-group specific requirements drive formulation constraints and stability demands. Recognizing these layered segmentation realities enables stakeholders to prioritize product portfolios and operational investments that match clinical needs and delivery channel realities.

Regionally differentiated intelligence on regulatory harmonization manufacturing capacity and programmatic priorities across varied global geographies that shape vaccine access and supply

Regional dynamics exert a decisive influence on vaccine strategy, shaping manufacturing footprints, regulatory timelines, and programmatic deployment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory agility and established immunization infrastructure support rapid introduction of combination products, while public and private payers increasingly emphasize value-based procurement and supply assurance mechanisms. Supply chain nodes in North and Latin America also prioritize cold chain optimization and data-driven coverage monitoring to address urban-rural disparities.

Within Europe, Middle East & Africa, heterogeneity in regulatory frameworks and procurement capacity creates a dual imperative: harmonize standards to enable efficient market entry, and strengthen local manufacturing and distribution capabilities to close access gaps. International partnerships and donor programs continue to play a vital role in many jurisdictions, necessitating alignment between global suppliers and regional program needs. In the Asia-Pacific, manufacturing scale and investment in biologics capability are significant drivers of global supply, while rising domestic demand and government-led manufacturing incentives are accelerating capacity expansion. Across all regions, investment in digital registries and supply chain transparency is improving demand forecasting and immunization coverage measurement, enabling more targeted interventions and better allocation of limited resources.

Strategic company-level perspective revealing how manufacturers are aligning technology investments supply resilience and stakeholder partnerships to sustain pediatric vaccine leadership

Company strategies in the pediatric vaccine space are converging toward three priority themes: technological differentiation, supply chain resilience, and collaborative engagement with public health systems. Leading biological producers are investing to broaden their combination and conjugate portfolios while extending capabilities in recombinant and subunit platforms that facilitate antigen updates and scalable manufacture. Concurrently, players are pursuing capacity enhancements, including modular fill-finish lines and geographically distributed manufacturing nodes, to mitigate disruption risk and to meet country-level sourcing preferences.

Industry participants are also deepening partnerships with contract development and manufacturing organizations, academic centers, and public-private consortia to accelerate development timelines and expand local production. Commercial approaches increasingly bundle product supply with value-added services such as cold chain strengthening, training for health workers, and data sharing agreements that support coverage monitoring. Pricing strategies reflect a balance between ensuring affordability for public programs and preserving margins that sustain ongoing R&D. For smaller or regional manufacturers, focusing on niche disease targets, cost-effective platforms, or specialized distribution agreements offers defensible positions that complement the broader strategies of multinational producers. Overall, corporate success is tied to the ability to integrate scientific innovation with pragmatic manufacturing and stakeholder collaboration.

Actionable recommendations that integrate product innovation supply diversification pricing strategies and stakeholder engagement to drive sustainable pediatric immunization outcomes

Industry leaders should pursue a coordinated set of actions that blend innovation, operational rigor, and stakeholder alignment to improve pediatric vaccine access and program outcomes. First, prioritize development of combination and conjugate formulations that reduce administration complexity and improve adherence, while ensuring that manufacturing investments support flexible production across multiple platforms. Second, invest in diversified sourcing strategies and regional manufacturing options to shield programs from external trade shocks and to meet procurement preferences for local supply assurance.

Third, strengthen end-user engagement by pairing product launches with training, cold chain support, and integration into digital immunization registries to enhance uptake and monitoring. Fourth, adopt tailored pricing and contracting models that balance affordability for public purchasers with incentives for sustained R&D investment, including outcome-based agreements and volume-linked supply commitments. Fifth, deepen collaborations with public health agencies, global donors, and clinical networks to align clinical trial design, post-marketing surveillance, and safety communication strategies. By executing these steps in parallel, companies and health systems can accelerate access to effective pediatric immunizations while building the operational foundations required for long-term program stability.

A transparent research methodology describing primary interviews secondary synthesis and analytical safeguards used to produce validated insights on pediatric vaccine dynamics

The research underpinning this executive summary synthesizes primary stakeholder input with rigorous secondary analysis to ensure balanced and verifiable insights. Primary data were gathered through structured interviews with vaccine developers, manufacturing leaders, procurement specialists, clinical program managers, and policy-makers, which provided real-world perspectives on supply chain constraints, regulatory priorities, and adoption barriers. These qualitative inputs were triangulated with secondary sources including regulatory guidance documents, peer-reviewed literature on vaccine technologies, publicly disclosed corporate filings related to capacity investments, and global immunization program reports to validate observed trends.

Analytical methods included thematic coding of interview data to identify recurring challenges and strategic responses, comparative technology assessment to evaluate platform advantages and constraints, and scenario analysis to explore implications of trade policy and manufacturing shifts. Quality assurance measures involved cross-validation of key findings with domain experts and review of technical assumptions against authoritative clinical and regulatory references. Limitations of the methodology include potential variability in stakeholder perspectives across jurisdictions and the rapidly evolving nature of vaccine science; nonetheless, the combination of primary and secondary inputs offers a robust foundation for the strategic conclusions presented herein.

A concise conclusion synthesizing technological promise operational constraints and strategic priorities that will determine pediatric immunization success

In summary, pediatric vaccines sit at the intersection of accelerating scientific capability and entrenched operational realities. Technological progress in conjugate, recombinant, and combination formulations presents clear pathways to broaden protection while simplifying schedules, yet programmatic adoption hinges on reliable supply, regulatory alignment, and sustained public trust. Trade policy developments and tariff shifts have highlighted the fragility of some global supply linkages and are catalyzing investment in regional capacity, which will reshape procurement relationships and regulatory collaboration in the coming years.

As stakeholders navigate this environment, the most successful strategies will combine targeted product portfolios with resilient manufacturing footprints, thoughtful contracting approaches, and integrated end-user support. Decision-makers who prioritize alignment across R&D, manufacturing, procurement, and program delivery will be best positioned to convert scientific advances into durable public health impact for infants, children, and adolescents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of mRNA technology in pediatric vaccine pipelines for emerging pathogens
  • 5.2. Increased adoption of combination vaccines to reduce injection burden in children
  • 5.3. Growth of digital tracking tools to improve pediatric vaccine adherence and coverage
  • 5.4. Rising focus on vaccine equity initiatives to expand access in underserved pediatric populations
  • 5.5. Development of needle-free delivery methods to enhance vaccine uptake among infants and toddlers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pediatric Vaccines Market, by Vaccine Type

  • 8.1. Hexavalent
  • 8.2. Monovalent
  • 8.3. Pentavalent
  • 8.4. Quadrivalent

9. Pediatric Vaccines Market, by Disease

  • 9.1. DTP
    • 9.1.1. Diphtheria
    • 9.1.2. Pertussis
    • 9.1.3. Tetanus
  • 9.2. Hepatitis B
  • 9.3. Hib
  • 9.4. Measles
  • 9.5. Pneumococcal
  • 9.6. Polio
  • 9.7. Rotavirus

10. Pediatric Vaccines Market, by Technology

  • 10.1. Conjugate
    • 10.1.1. Polysaccharide Conjugate
    • 10.1.2. Protein Conjugate
  • 10.2. Inactivated
    • 10.2.1. Toxoid
    • 10.2.2. Viral
  • 10.3. Live Attenuated
    • 10.3.1. Bacterial
    • 10.3.2. Viral
  • 10.4. Recombinant
    • 10.4.1. Mammalian Cell Culture
    • 10.4.2. Yeast Based
  • 10.5. Subunit
    • 10.5.1. Peptide Subunit
    • 10.5.2. Protein Subunit

11. Pediatric Vaccines Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Immunization Centers
  • 11.4. Pharmacies
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies

12. Pediatric Vaccines Market, by Age Group

  • 12.1. Adolescents
  • 12.2. Children
  • 12.3. Infants
  • 12.4. Neonates
  • 12.5. Toddlers

13. Pediatric Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pediatric Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pediatric Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Serum Institute of India Private Limited
    • 16.3.6. Bharat Biotech International Limited
    • 16.3.7. PT Bio Farma (Persero)
    • 16.3.8. Sinovac Biotech Ltd.
    • 16.3.9. CSL Seqirus Pty Ltd.
    • 16.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PEDIATRIC VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PEDIATRIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PEDIATRIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEXAVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DTP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY YEAST BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PEPTIDE SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY IMMUNIZATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY NEONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TODDLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025-2032 (USD MILLIO